General and Laparoscopic Surgery Unit, S. Giovanni Bosco Hospital, Naples, Italy.
Obes Surg. 2012 Oct;22(10):1535-9. doi: 10.1007/s11695-012-0657-5.
Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are performed in patients with obesity and type 2 diabetes mellitus (T2DM). The aim of this study is to evaluate retrospectively the clinical efficacy of RYGB and SG in two groups of obese T2DM patients.
From the hospital database, we extracted the clinical records of 31 obese T2DM patients, of whom 15 (7 F/8 M) had undergone laparoscopic SG (LSG) and 16 (7 F/9 M) laparoscopic RYGB (LRYGB) in the period 2005-2008. The groups were comparable for age (range 33-59 years) and BMI (range 38-57 kg/m(2)). LRYGB alimentary limb was 150 cm, and biliopancreatic limb was 150 cm from the Treitz ligament. LSG vertical transection was calibrated on a 40-Fr orogastric bougie. Data were analysed at 6, 12 and 18-24 months with reference to weight loss and remission of comorbidities.
The reduction in body weight was comparable in the two groups. At 18-24 months the percent BMI reduction was 29 ± 8 and 33 ± 11 % in LSG and LRYGB, respectively. Percent excess weight loss was 53 ± 16 and 52 ± 19 % in LSG and LRYGB, respectively. Thirteen patients in LSG and 14 patients in LRYGB discontinued their hypoglycaemic medications. Five (55 %) patients in LSG and eight (89 %) in LRYGB discontinued antihypertensive drugs. Three out of five patients in LSG and one out of two patients in LRYGB withdrew lipid-lowering agents.
LSG and LRYGB are equally effective in terms of weight loss and remission of obesity-related comorbidities. Controlled long-term comparisons are needed to establish the optimal procedure in relation to patients' characteristics.
Roux-en-Y 胃旁路术(RYGB)和袖状胃切除术(SG)用于肥胖和 2 型糖尿病(T2DM)患者。本研究旨在回顾性评估两组肥胖 T2DM 患者的 RYGB 和 SG 的临床疗效。
我们从医院数据库中提取了 31 例肥胖 T2DM 患者的临床记录,其中 15 例(7 名女性/8 名男性)接受了腹腔镜 SG(LSG),16 例(7 名女性/9 名男性)接受了腹腔镜 RYGB(LRYGB)。两组患者的年龄(33-59 岁)和 BMI(38-57kg/m2)相似。LRYGB 消化道长度为 150cm,胆胰肠吻合口距Treitz 韧带 150cm。LSG 垂直横断长度为 40Fr 胃镜引导。在 6、12 和 18-24 个月时,根据体重减轻和并发症缓解情况进行数据分析。
两组体重减轻情况相当。18-24 个月时,LSG 和 LRYGB 的 BMI 降低率分别为 29%±8%和 33%±11%。LSG 和 LRYGB 的多余体重减轻率分别为 53%±16%和 52%±19%。LSG 组 13 例患者和 LRYGB 组 14 例患者停止使用降糖药物。LSG 组 5 例(55%)和 LRYGB 组 8 例(89%)患者停止使用降压药。LSG 组 3 例(33%)和 LRYGB 组 1 例(50%)患者停用降脂药。
LSG 和 LRYGB 在体重减轻和缓解肥胖相关并发症方面同样有效。需要进行长期对照研究,以确定与患者特征相关的最佳手术方式。